ANI Pharmaceuticals amends bylaws to adopt universal proxy rules, update DGCL provisions, add forum selection clause

ANI PHARMACEUTICALS INC

Board approved Second Amended and Restated Bylaws effective Feb 28, 2023, incorporating universal proxy rules and recent DGCL amendments.
Quorum for stockholder meetings (other than Board-called) changed to majority of voting power; stockholder list requirement removed.
Enhanced disclosure and procedural requirements for stockholder proposals and director nominations, including universal proxy compliance.
Indemnification provisions updated with mandatory advancement of expenses subject to Board consent; forum selection clause added for Delaware and federal courts.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ANI PHARMACEUTICALS INC: Board adopted Second Amended and Restated Bylaws with clarifying amendments, updates for universal proxy rules and DGCL, including changes to quorum requirements, stockholder proposal procedures, director nomination procedures, indemnification provisions, and a forum selection clause (effective 2023-02-28).

Change: bylaw amendment
Effective: 2023-02-28

Exact text from the filing

On February 28, 2023, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) approved the Second Amended and Restated Bylaws of the Company (the “Bylaws”), which became effective immediately.

View on SEC.gov

Browse all governance changes →

ANI PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-029038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.